Vinca Alkaloid

5 Drugs classified under this drug class

Vinca Alkaloid. Vinblastine Sulphate 1 mg/ml.
VIALS: 10 mg. I.V. inject. Initial: Adults:
Single dose 0.1 mg/kg (3.7 mg/m2) 1 x
wkly, follow. by leukocyte count. Child:
Single dose 2.5 mg/m2, follow. by
leukocyte count. Maint. ther., liver, ren.
funct. disords., combinat. ther: See lit.
Tmt. of follow. neoplasms, alone/in
conjunct. with other oncolyt. drugs: Freq.
respons. maligns: General. Hodgkin’s dis.
(stages III and IV, Ann Arbor modific. of Rye
staging system); non-Hodgkin’s
lymphoma, reticulum-cell sarcoma,
lymphosarcoma, mycosis fungoides,
neuroblastoma, Histiocytosis X. Less freq.
respons. maligns: Choriocarcinoma resist.
to other chemotherapeut. agents,
embryonal carcinoma of the testis,
carcinoma of the breast, unrespons. to
approp. endocrine surrg and hormonal
ther.
C/I: Hypersens. to vinblastine or other
vinca-alkaloids, excipients. Leukopen.
not relat. to tumor, severe uncontroll.
infect. Such infects. must first be
controll. with antiseptics/antibiotics bef.
admin. vinblastine, intrathecal admin.
vinblastine.

Vinca Alkaloid. Vinorelbine 10mg/ml.
VIALS (conc. sol. for. infuse.): 1 ml, 5 ml x
10 mg/ml. For I.V. admin. Dosage must be individ. adjust. for each pt. accord. to indic. and pt. med. cond.
Non small cell lung cancer, advanced
breast cancer, hormone refract.
Prostatecancer, espec. in comb. with low
dose oral cortico-ther. or estramustine.
C/I: Known hypersens. Vinorelbine or
other vinca alk.
Neutrophil count < 1500/mm3 or sev.
infec. curr., recent (within 2 weeks).
Platelet count < 100000/mm3. comb.
with yellow fev.vac. Preg., lact.
Addit. only for oral use prepar.: Dis.
signific. affect. absorp. Prev. sign.surg.
resec. of stomach, small bow.
Sev. hep. insuffic. Pts. require.g longterm
oxygen ther.

Vinca Alkaloid. Vinorelbine 20 mg, 30 mg.
CAPS: 1 x 20 mg, 30 mg. As single agent,
to be tak en with food. 1st 3 admins: 60
mg/m2 bdy surface area 1 x wkly.
Subseq. admins: Incr. to 80 mg/m2 1 x
wkly except when neutrophil count
dropped. Dosage must be individ.
adjust. for each pt. accord. to indic. and
pt. med. cond.
Non small cell lung cancer, advanced
breast cancer.
C/I: Known hypersens. Vinorelbine or
other vinca alk.
Neutrophil count < 1500/mm3 or sev.
infec. curr., recent (within 2 weeks).
Platelet count < 100000/mm3. comb.
with yellow fev.vac. Preg., lact.
Addit. only for oral use prepar.: Dis.
signific. affect. absorp. Prev. sign.surg.
resec. of stomach, small bow.
Sev. hep. insuffic. Pts. require.g longterm
oxygen ther.

Vinca Alkaloid. Vincristine Sulphate 1 mg/ml.
VIALS: 1 ml, 2 ml, 5ml. See lit.
Acute leukem., malign. lymphomas (incl.
Hodgkin’s dis.), lympho-sarcoma,
reticulum cell, sarcoma, neuroblastoma,
Wilm’s tumor, rhabdomyosarcoma.

Vinca Alkaloid. Vinorelbine (as tartrate) 10 mg/ml.
VIALS: 1 x 10 mg/ml; 1 x 50 mg/5 ml. I.V.
use. Adjust accord. indicat., gen. cond.,
hepat./ren. funct., concurr. chemother.,
blood counts.
Non-small cell lung cancer, advanced
breast cancer, hormone-refract. prostate
cancer espec. in comb. with low dose oral
corticoid ther. or Estramustin.
C/I: Hypersens., neutrophil counts below
2,000/mm3, severe current/recent
infect., pregn., lact. Intrathecal admin.